Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
Jaccard, Arnaud; Bridoux, Frank; Roeloffzen, Wilfried; Minnema, Monique C; Bergantim, Rui; Hájek, Roman; João, Cristina; Cibeira, M Teresa; Palladini, Giovanni; Schönland, Stefan; Merlini, Giampaolo; Milani, Paolo; Dimopoulos, Meletios A; Ravichandran, Sriram; Hegenbart, Ute; Agis, Hermine; Gros, Blanca; Asra, Aisha; Magarotto, Valeria; Cheliotis, Giorgos; Psarros, Giorgos; Sonneveld, Pieter; Wechalekar, Ashutosh; Kastritis, Efstathios
(2024) Clinical Lymphoma, Myeloma and Leukemia, volume 24, issue 5, pp. e205 - e216
(Article)
Abstract
OBJECTIVES: To report healthcare resource utilization (HCRU) and safety outcomes in systemic light chain (AL) amyloidosis from the EMN23 study. MATERIALS AND METHODS: The retrospective, observational, multinational EMN23 study included 4,480 patients initiating first-line treatment for AL amyloidosis in 2004-2018 and assessed, among other objectives, HCRU and safety outcomes. HCRU
... read more
included hospitalizations, examinations, and dialysis; safety included serious adverse events (SAEs) and adverse events of special interest (AESIs). Data were descriptively analyzed by select prognostic factors (e.g., cardiac staging by Mayo2004/European) for 2004-2010 and 2011-2018. A cost-of-illness analysis was conducted for the UK and Spain. RESULTS: HCRU/safety and dialysis data were extracted for 674 and 774 patients, respectively. Of patients with assessed cardiac stage (2004-2010: 159; 2011-2018: 387), 67.9% and 61.0% had ≥ 1 hospitalization, 56.0% and 51.4% had ≥ 1 SAE, and 31.4% and 28.9% had ≥ 1 AESI across all cardiac stages in 2004-2010 and 2011-2018, respectively. The per-patient-per-year length of hospitalization increased with disease severity (cardiac stage). Of patients with dialysis data (2004-2010: 176; 2011-2018: 453), 23.9% and 14.8% had ≥ 1 dialysis session across all cardiac stages in 2004-2010 and 2011-2018, respectively. The annual cost-of-illness was estimated at €40,961,066 and €31,904,386 for the UK and Spain, respectively; dialysis accounted for ∼28% (UK) and ∼35% (Spain) of the total AL amyloidosis costs. CONCLUSIONS: EMN23 showed that the burden of AL amyloidosis is substantial, highlighting the need for early disease diagnosis and effective treatments targeting the underlying pathology.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Cost-of-ilness, Health economics, Dialysis, HCRU, Hematology, Oncology, Cancer Research, Journal Article
ISSN: 2152-2650
Publisher: Cancer Media Group
Note: Publisher Copyright: © 2024 Elsevier Inc.
(Peer reviewed)